Communiqués J. Molner

Actions

MOLNR

EE3100109034

Produits pharmaceutiques

Marché Fermé - Nasdaq Tallinn 15:30:00 14/09/2026			Varia. 5j.	Varia. 1 janv.
17,50 ^EUR	+0,57%		-2,78%	-37,50%

02/06	J. Molner AS (TLSE:MOLNR) fait l'acquisition d'un portefeuille de produits pharmaceutiques génériques et de spécialité commercialisés aux États-Unis auprès de Nordic Pharma, Inc.	CI
10/12/24	J. Molner AS renforce sa position sur le marché américain grâce à un accord de développement de nouveaux produits	CI

Communiqués

30/06	J Molner : Decisions of the shareholders - adoption of resolutions of the general meeting without calling a meeting	PU
17/06	J Molner : Chief Financial Officer of J Molner AS resigns	PU
08/06	J Molner : Notice of J. Molner AS Regarding the Adoption of a Shareholders' Resolution Without Convening a General Meeting	PU
08/06	J Molner : Audited Consolidated Annual Report 2025	PU
02/06	J Molner : acquires US commercial pharmaceutical portfolio from Nordic Pharma, Inc.	PU
01/06	J Molner : acquires J Molner Holdings Inc. and enters into a loan agreement	PU
26/05	J Molner : Changes in the Capital Structure of J. Molner AS	PU
29/04	J Molner : Subsidiary of J. Molner AS entered into a commercial pledge agreement	PU
09/01	J Molner : Changes in the capital structure of J. Molner AS	PU
30/12	J Molner : Additional increase of The J. Molner Company OÜ voluntary reserve	PU
18/12	J Molner : Increase of J. Molner share capital in connection with a capital structure adjustment transaction	PU
05/12	J Molner : Decisions of the shareholders - adoption of resolutions of the General Meeting without calling a meeting	PU
14/11	J Molner : launches Clobetasol Propionate Cream USP, 0.05% (Emollient) in the United States	PU
01/09/25	J Molner : extension of Management Board Member terms of office	PU
30/06/25	J Molner : Additional increase of The J. Molner Company OÜ voluntary reserve	PU
06/06/25	J Molner : announces changes in the management of The J. Molner Company LLC	PU
22/05/25	J Molner : Decisions of the shareholders - adoption of resolutions of the General Meeting without calling a meeting	PU
05/05/25	J Molner : Notice of J. Molner AS Regarding the Adoption of a Shareholders' Resolution Without Convening a General Meeting	PU
25/04/25	J Molner : Option Agreement Signed with Key Employee	PU
21/04/25	J Molner : Audited Consolidated Annual Report 2024	PU
10/12/24	J Molner : The subsidiary of J. Molner AS The J. Molner Company OÜ was granted an additional loan	PU
10/12/24	J Molner : strengthens US market position with new product development agreement	PU
04/12/24	J Molner : Announces Approval and Upcoming Market Launch of Desoximetasone Ointment USP, 0.05%	PU
12/11/24	J Molner : launches Lidocaine HCL Topical Solution USP, 4% in the United States	PU
22/10/24	J Molner : Announces New Chief Financial Officer	PU